[go: up one dir, main page]

WO2013130577A3 - Compositions and methods for the treatment of migraine - Google Patents

Compositions and methods for the treatment of migraine Download PDF

Info

Publication number
WO2013130577A3
WO2013130577A3 PCT/US2013/027983 US2013027983W WO2013130577A3 WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3 US 2013027983 W US2013027983 W US 2013027983W WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3
Authority
WO
WIPO (PCT)
Prior art keywords
migraine
treatment
alpha
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/027983
Other languages
French (fr)
Other versions
WO2013130577A2 (en
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Therapies LLC
Original Assignee
Eye Therapies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/406,321 external-priority patent/US20120156244A1/en
Application filed by Eye Therapies LLC filed Critical Eye Therapies LLC
Priority to EP13754567.9A priority Critical patent/EP2819674A2/en
Priority to CA2865593A priority patent/CA2865593A1/en
Priority to JP2014558959A priority patent/JP2015517980A/en
Publication of WO2013130577A2 publication Critical patent/WO2013130577A2/en
Anticipated expiration legal-status Critical
Publication of WO2013130577A3 publication Critical patent/WO2013130577A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical compositions for the treatment of migraine, wherein the pharmaceutical composition formulated as a nasal spray or as a oral formulation comprises low concentrations of a superselective subclass of alpha-2 adrenergic receptor agonists, that have a binding affinity of 900 fold or greater for alpha-2 over alpha-1 adrenergic receptors, such as, for example, dexmedetomidine.
PCT/US2013/027983 2012-02-27 2013-02-27 Compositions and methods for the treatment of migraine Ceased WO2013130577A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP13754567.9A EP2819674A2 (en) 2012-02-27 2013-02-27 Compositions and methods for the treatment of migraine
CA2865593A CA2865593A1 (en) 2012-02-27 2013-02-27 Compositions and methods for the treatment of migraine
JP2014558959A JP2015517980A (en) 2012-02-27 2013-02-27 Compositions and methods for the treatment of migraine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/406,321 2012-02-27
US13/406,321 US20120156244A1 (en) 2008-08-01 2012-02-27 Nasal Compositions and Uses Thereof

Publications (2)

Publication Number Publication Date
WO2013130577A2 WO2013130577A2 (en) 2013-09-06
WO2013130577A3 true WO2013130577A3 (en) 2015-03-12

Family

ID=49083441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/027983 Ceased WO2013130577A2 (en) 2012-02-27 2013-02-27 Compositions and methods for the treatment of migraine

Country Status (4)

Country Link
EP (1) EP2819674A2 (en)
JP (1) JP2015517980A (en)
CA (1) CA2865593A1 (en)
WO (1) WO2013130577A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259440A1 (en) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 Nasal spray of dexmedetomidine, preparation method therefor and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
WO2014121027A1 (en) 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
EP4368169A3 (en) 2016-12-31 2024-08-07 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
WO2019113425A1 (en) * 2017-12-08 2019-06-13 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
MX2020014000A (en) 2018-06-27 2021-06-15 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them.
US12161629B2 (en) 2018-10-15 2024-12-10 Opus Genetics, Inc. Methods and compositions for treatment of glaucoma and related conditions
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
AU2020316013A1 (en) 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
CN115368310B (en) 2021-05-18 2025-06-27 奥库菲尔医药公司 Method for synthesizing phentolamine mesylate
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486190B1 (en) * 1997-11-24 2002-11-26 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US20020192288A1 (en) * 2000-06-26 2002-12-19 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof
US20110257188A1 (en) * 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486190B1 (en) * 1997-11-24 2002-11-26 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US20020192288A1 (en) * 2000-06-26 2002-12-19 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US20090220611A1 (en) * 2005-09-30 2009-09-03 Frederic Dargelas Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same
US20110257188A1 (en) * 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
US20110021588A1 (en) * 2009-05-15 2011-01-27 Recro Pharma, Inc. Sublingual dexmeditomidine compositions and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020259440A1 (en) * 2019-06-28 2020-12-30 四川普锐特药业有限公司 Nasal spray of dexmedetomidine, preparation method therefor and use thereof

Also Published As

Publication number Publication date
EP2819674A2 (en) 2015-01-07
WO2013130577A2 (en) 2013-09-06
CA2865593A1 (en) 2013-09-06
JP2015517980A (en) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2013130577A3 (en) Compositions and methods for the treatment of migraine
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
UA95644C2 (en) Pyridizinone derivative, pharmaceutical composition and treatment method
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
WO2010042652A3 (en) Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
WO2010054113A3 (en) Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
WO2009115547A8 (en) Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2008121348A8 (en) Peripheral opioid receptor antagonists and uses thereof
WO2010014172A3 (en) Delivery particle
WO2010092088A3 (en) Use of hydrophobin as a spreading agent
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13754567

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2865593

Country of ref document: CA

Ref document number: 2014558959

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013754567

Country of ref document: EP